Company intelligence / Profile preview

AbelZeta

Rockville, Maryland, United States

Ownership: Private
Development stage: Other

Overview

AbelZeta has demonstrated high response rates and durable remissions in relapsed/refractory B-cell lymphoma with its lead CAR-T program C-CAR039 (dual CD19/CD20), and obtained FDA RMAT designation for C-CAR168 in refractory SLE/LN. Earlier results support a best-in-class potential, with 4-year overall response and complete response rates of 91.5% and 85.1% for C-CAR039, and collaborations indicate broad indicator exploration.

Therapeutic areas: OncologyImmunology
Modalities: CAR-T cell therapyCell therapyTumor-infiltrating lymphocyte therapy
Industry: Biotech

Drug pipeline

24 assets

C-CAR168

23 more assets in the full pipeline.

Request access →

Partnerships

Janssen Biotech (Johnson & Johnson) – global license and collaboration for two autologous CD20-directed CAR-Ts

Beyond the preview

Go deeper on AbelZeta.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AbelZeta.

Explore the full profile